• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

SGLT2 inhibitors are antihyperglycemic drugs that protect kidneys and the heart of patients
with or without type 2 diabetes and preserved or reduced kidney function from failing. The …

2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk
Reduction in Patients With Type 2 Diabetes: A Report of the American College of …

Cardiorenal syndrome encompasses a spectrum of disorders involving both the heart and
kidneys in which acute or chronic dysfunction in 1 organ may induce acute or chronic …

Approximately 6% of adults worldwide have atherosclerosis and thrombosis of the lower
limb arteries (peripheral artery disease (PAD)) and the prevalence is rising. PAD causes leg …

The management of type 2 diabetes mellitus (T2DM) is becoming increasingly complex.
Sodium–glucose cotransporter type 2 inhibitors (SGLT2is) are the newest antidiabetic …

Background: SGLT2 (sodium-glucose cotransporter 2) inhibitors lower cardiovascular
events in type 2 diabetes mellitus but whether they promote direct cardiac effects remains …

Abstract Sodium–glucose cotransporter (SGLT) 2 inhibitors have been demonstrated to
reduce cardiovascular events, particularly heart failure, in cardiovascular outcome trials …

SGLT2 inhibitors have profound benefits on reducing heart failure and cardiovascular
mortality in individuals with type 2 diabetes, although the mechanism (s) of this benefit …

Background: In the EMPA-REG OUTCOME trial (BI 10773 [Empagliflozin] Cardiovascular
Outcome Event Trial in Type 2 Diabetes Mellitus Patients) in patients with type 2 diabetes …